RxDoctor Payments Data

Alyssa Malone

Nurse Practitioner · Fort Wayne, INNPI 1649707068

Payments from drug & device makers

$1,658in general payments, 2019–2025

Across 58 payments — averaging $28.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axsome Therapeutics, Inc.$282
  • Lilly USA, LLC$267
  • AbbVie$262
  • Corium, LLC$242
  • AstraZeneca$200
  • Idorsia Pharmaceuticals US Inc$142
  • plus $264 from 6 others

What the payments were for

  • Food & beverage$1,658100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,658 in reported general payments places this provider in the 80th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Medicare billing

Part B allowed, 2024
$32,796
Medicare patients
147
Services billed
977

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide32$47,542
MounjaroTirzepatide12$12,589
LantusInsulin Glargine,hum.Rec.Anlog14$3,384
Gabapentin65$1,274
SynthroidLevothyroxine Sodium12$1,169
Albuterol Sulfate HfaAlbuterol Sulfate40$1,030
Nano 2nd Gen Pen NeedlePen Needle, Diabetic14$1,012
Desvenlafaxine Succinate ErDesvenlafaxine Succinate11$984
Omeprazole39$785
Metformin Hcl32$720
Levothyroxine Sodium79$660
Atorvastatin Calcium87$601
Trazodone Hcl46$533
Fluticasone Propionate21$464
Tamsulosin Hcl18$399

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$31$47,54232 claims
Lilly USA, LLCMounjaro$267$12,58912 claims
AbbVieSynthroid$262$1,16912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →